← All trials
NCT05703685
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 22, 2023
- Primary completion
- Oct 3, 2024
- Completion date
- Apr 11, 2025
- First posted
- Jan 30, 2023
- Last posted
- Dec 21, 2023
- Enrollment
- 56
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Mental Health (NIMH)Lead sponsor
- National Institute of Mental Health (NIMH)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.